Dr. Bardia is an internationally renowned breast oncologist known for his pioneering clinical and translational research in the field of cancer therapeutics, particularly antibody drug conjugates. Dr. Bardia led the development of sacituzumab govitecan, the first ADC approved for patients with metastatic triple negative breast cancer, as well as other including trastuzumab deruxtecan and datapotamab deruxtecan. Dr. Bardia also led the clinical development of elacestrant, the first oral SERD approved for patients with metastatic HR+ positive breast cancer. In translational collaboration with various labs, identified role of ESR1 mutations in mediating endocrine resistance, RB1 mutations in mediating CDK 4/6i resistance and TOP1 mutations in mediating ADC resistance. Besides cutting-edge research, Dr. Bardia is highly regarded among peers as an excellent mentor and strong advocate for academic trainees and junior faculty members. Dr. Bardia has received several awards including outstanding award for research excellence at Mayo Clinic, Young Investigator Award from ASCO, Distinguished researcher award from MASCO, and Douglas Family Foundation prize for excellence in oncology research.

Dr Aditya Bardia has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consultant/Advisory board: Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics/Gilead, Sanofi, Daiichi Pharma/Astra Zeneca, Eli Lilly, Mersana. Contracted Research/Grant (to institution): Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Pharma/Astra Zeneca, Eli Lilly.